REVOLUTION MEDICINES INC (RVMD)
US76155X1000 - Common Stock
Overall RVMD gets a fundamental rating of 3 out of 10. We evaluated RVMD against 565 industry peers in the Biotechnology industry. While RVMD has a great health rating, there are worries on its profitability. RVMD is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RVMD has reported negative net income.
In the past year RVMD has reported a negative cash flow from operations.
RVMD had negative earnings in each of the past 5 years.
In the past 5 years RVMD always reported negative operating cash flow.
1.2 Ratios
RVMD's Return On Assets of -32.16% is fine compared to the rest of the industry. RVMD outperforms 65.06% of its industry peers.
RVMD has a Return On Equity of -36.20%. This is in the better half of the industry: RVMD outperforms 75.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.16% | ||
| ROE | -36.2% | ||
| ROIC | N/A |
ROA(3y)-25.72%
ROA(5y)-24.94%
ROE(3y)-30.41%
ROE(5y)-31.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RVMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RVMD has more shares outstanding
The number of shares outstanding for RVMD has been increased compared to 5 years ago.
There is no outstanding debt for RVMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 27.84 indicates that RVMD is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 27.84, RVMD belongs to the top of the industry, outperforming 95.37% of the companies in the same industry.
There is no outstanding debt for RVMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 27.84 |
ROIC/WACCN/A
WACC10.41%
2.3 Liquidity
A Current Ratio of 14.24 indicates that RVMD has no problem at all paying its short term obligations.
The Current ratio of RVMD (14.24) is better than 88.24% of its industry peers.
RVMD has a Quick Ratio of 14.24. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
RVMD has a better Quick ratio (14.24) than 88.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.24 | ||
| Quick Ratio | 14.24 |
3. Growth
3.1 Past
The earnings per share for RVMD have decreased strongly by -10.02% in the last year.
The Revenue for RVMD has decreased by -97.16% in the past year. This is quite bad
Measured over the past years, RVMD shows a very negative growth in Revenue. The Revenue has been decreasing by -10.50% on average per year.
EPS 1Y (TTM)-10.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.34%
Revenue 1Y (TTM)-97.16%
Revenue growth 3Y-35.41%
Revenue growth 5Y-10.5%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, RVMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.72% on average per year.
RVMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 118.18% yearly.
EPS Next Y6.89%
EPS Next 2Y-4.64%
EPS Next 3Y-4.75%
EPS Next 5Y14.72%
Revenue Next Year-97.49%
Revenue Next 2Y-68.3%
Revenue Next 3Y12.09%
Revenue Next 5Y118.18%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RVMD. In the last year negative earnings were reported.
Also next year RVMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as RVMD's earnings are expected to decrease with -4.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.64%
EPS Next 3Y-4.75%
5. Dividend
5.1 Amount
RVMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REVOLUTION MEDICINES INC
NASDAQ:RVMD (11/21/2024, 8:00:02 PM)
After market: 58.75 +1.97 (+3.47%)56.78
-0.29 (-0.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.55B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.16% | ||
| ROE | -36.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 14.24 | ||
| Quick Ratio | 14.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-10.02%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y6.89%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-97.16%
Revenue growth 3Y-35.41%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y